Cite
HARVARD Citation
Rini, B. et al. (2019). Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 393 (10189), pp. 2404-2415. [Online].